Author

L. Shuai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 2 Organism:human· 1 Organism:rat· 1

Frequent Co-Authors

C. Wang· 3 shared Z. Wen· 2 shared C. Peng· 1 shared C. Schindewolf· 1 shared C.-I. Wu· 1 shared F. Guo· 1 shared F.-J. Zhang· 1 shared F.-L. Liu· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. Wang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintAug 10, 2022

Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro

N. Hou, L. Shuai, L. Zhang…·Q. Hu

This study develops a potent non-covalent inhibitor of SARS-CoV-2 3CLpro, showing effective antiviral activity in human cells and animal models.

DOI 10.1101/2022.08.10.503531

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintApr 16, 2021

Homo-harringtonine (HHT) - A highly effective drug against coronaviruses and the potential for large-scale clinical applications

H.-J. Wen, P. Lin, G.-X. Zhong…·C.-I. Wu

The paper identifies Homo-harringtonine (HHT) as a potent antiviral drug against coronaviruses, effective in mouse models and safe in dogs, with potential for large-scale clinical use.

DOI 10.1101/2021.04.16.440104

𝕏 PostBluesky

MicrobiologybioRxivNov 12, 2020

The Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract

Y. Shi, L. Shuai, Z. Wen…·G. Peng

This paper evaluates the antiviral efficacy of GS441524 and GC376 combination therapy against SARS-CoV-2 in a mouse model, showing synergistic effects and protection with low-dose combined treatment.

DOI 10.1080/22221751.2021.1899770

mouseexperimental assay

𝕏 PostBluesky